Cargando…

Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma

Therapeutic options for metastatic poorly differentiated neuroendocrine carcinoma (NEC) after prior platinum‐based chemotherapy are limited. Topotecan is an approved second‐line chemotherapy for small cell lung cancer (SCLC). NEC is often considered to show a biological behavior similar to SCLC. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Apostolidis, Leonidas, Bergmann, Frank, Jäger, Dirk, Winkler, Eva Caroline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055186/ https://www.ncbi.nlm.nih.gov/pubmed/27456539 http://dx.doi.org/10.1002/cam4.807

Ejemplares similares

Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas
por: Olsen, Ingrid Holst, et al.
Publicado: (2014)

Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3)
por: Apostolidis, Leonidas, et al.
Publicado: (2021)

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2023)

Optimization of liposomal topotecan for use in treating neuroblastoma
por: Chernov, Lina, et al.
Publicado: (2017)

Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate
por: Apostolidis, Leonidas, et al.
Publicado: (2019)

Intra‐CSF topotecan in treatment of breast cancer patients with leptomeningeal metastases
por: Jaeckle, Kurt A., et al.
Publicado: (2020)

Epidemiology and Retrospective Analysis in Extrapulmonary Neuroendocrine Carcinoma
por: Sethi, Ashish, et al.
Publicado: (2021)

Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer
por: Rosen, Virginia M., et al.
Publicado: (2017)

Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma
por: Mishima, Saori, et al.
Publicado: (2018)

A single center’s experience of the extrapulmonary neuroendocrine carcinomas
por: Celik, Emir, et al.
Publicado: (2021)

Prognostic value of neuron-specific enolase in patients with advanced and metastatic non-neuroendocrine non-small cell lung cancer
por: Yan, Peng, et al.
Publicado: (2021)

Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies
por: Reed, Damon R., et al.
Publicado: (2015)

Post-Topotecan Mixed Response and ‘Redifferentiation-akin’ Phenomenon on Dual Tracer PET-CT in Multiple Treatment-Resistant Metastatic Neuroendocrine Neoplasm
por: Loharkar, Sarvesh, et al.
Publicado: (2023)

The Pretreatment Systemic Inflammatory Response is an Important Determinant of Poor Pathologic Response for Patients Undergoing Neoadjuvant Therapy for Rectal Cancer
por: Dreyer, Stephan B., et al.
Publicado: (2016)

Phase II study of temozolomide monotherapy in patients with extrapulmonary neuroendocrine carcinoma
por: Kobayashi, Noritoshi, et al.
Publicado: (2021)

Future therapeutic strategies in the treatment of extrapulmonary neuroendocrine carcinoma: a review
por: Robinson, Matthew D., et al.
Publicado: (2023)

Serum‐derived exosomes from mice with highly metastatic breast cancer transfer increased metastatic capacity to a poorly metastatic tumor
por: Gorczynski, Reginald M., et al.
Publicado: (2016)

Leptomeningeal Carcinomatosis: A Clinical Dilemma in Neuroendocrine Neoplasms
por: Apostolidis, Leonidas, et al.
Publicado: (2021)

A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer
por: Tinker, Anna V., et al.
Publicado: (2023)

High Pretreatment Plasma D-dimer Levels Are Associated With Poor Prognosis in Patients With Ovarian Cancer Independently of Venous Thromboembolism and Tumor Extension
por: Sakurai, Manabu, et al.
Publicado: (2015)

The patient-level effect of the cost of Cancer care – financial burden in German Cancer patients
por: Mehlis, Katja, et al.
Publicado: (2020)

Commentary: Periocular topotecan for retinoblastoma
por: Sharma, Minal, et al.
Publicado: (2018)

Is aspiration as detected on pretreatment video fluorography, a harbinger of poor quality of life and early mortality in cancers of the upper aerodigestive tract treated with radiotherapy?
por: Lal, Punita, et al.
Publicado: (2014)

Strong antitumor efficacy of a pancreatic tumor‐targeting oncolytic adenovirus for neuroendocrine tumors
por: Yamamoto, Yuki, et al.
Publicado: (2017)

Nanoplatform for the Delivery of Topotecan in the Cancer Milieu: An Appraisal of its Therapeutic Efficacy
por: Alshammari, Mohammed Kanan, et al.
Publicado: (2022)

High-Dose Lanreotide in the Treatment of Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: A Case Report
por: Van Fraeyenhove, Frank, et al.
Publicado: (2014)

Pretreatment C‐reactive protein/albumin ratio is associated with poor survival in patients with stage IB‐IIA cervical cancer
por: Zhang, Weiwei, et al.
Publicado: (2017)

Metastatic Extrapulmonary Small Cell Carcinoma Presenting as Obstructive Jaundice
por: Shah, Ejaz, et al.
Publicado: (2022)

Topotecan and Cyclophosphamide in Adults with Relapsed Sarcoma
por: Blanchette, P., et al.
Publicado: (2012)

Periocular topotecan for vitreous seeds in retinoblastoma
por: Sthapit, Purnima R, et al.
Publicado: (2018)

Lung dendritic cells facilitate extrapulmonary bacterial dissemination during pneumococcal pneumonia
por: Rosendahl, Alva, et al.
Publicado: (2013)

Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma
por: De Divitiis, C., et al.
Publicado: (2016)

Sex differences in metastatic surgery following diagnosis of synchronous metastatic colorectal cancer
por: Ljunggren, Malin, et al.
Publicado: (2022)

Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer
por: Di Desidero, Teresa, et al.
Publicado: (2015)

A Novel Radiographic Pattern Related to Poor Prognosis in Patients with Prostate Cancer with Metastatic Spinal Cord Compression
por: Wänman, Johan, et al.
Publicado: (2022)

Salvage PRRT with (177)Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival
por: Rudisile, S., et al.
Publicado: (2019)

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
por: Wong, Chung, et al.
Publicado: (2012)

Clinicopathological features and lymph node and distant metastasis patterns in patients with gastroenteropancreatic mixed neuroendocrine‐non‐neuroendocrine neoplasm
por: Zhang, Panpan, et al.
Publicado: (2021)

A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite‐stable metastatic colorectal cancer
por: Patel, Manish R., et al.
Publicado: (2021)

High pretreatment plasma Epstein‐Barr virus (EBV) DNA level is a poor prognostic marker in HIV‐associated, EBV‐negative diffuse large B‐cell lymphoma in Malawi
por: Montgomery, Nathan D., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ko58obocjlhr79nkl8j7n7gb35